Navigation Links
Nearly 1,400 Animal Shelters and Rescues, in Partnership With Veterinarians, Build Community Immunity Against Canine Influenza
Date:12/5/2011

TUCSON, Ariz., Dec. 5, 2011 /PRNewswire/ -- Nearly one million doses of the NOBIVAC Canine Flu H3N8 vaccine were donated to approximately 1,400 animal shelters and rescue groups in 49 states as part of the "Building Community Immunity" Program, a joint effort between the Petfinder.com Foundation and Merck Animal Health.   The grant was designed to help build community immunity against the canine influenza virus (CIV), better known as dog flu by encouraging vaccination of all adopted dogs and through wellness education and collaboration between the animal sheltering and local veterinary communities.  Each grant recipient received up to a four-month, two-dose per dog supply of the vaccine. 

Canine flu is a highly contagious disease that spreads easily from dog to dog, especially those in close proximity.  Nearly 100 percent of newly exposed dogs will contract the disease.  In a survey completed by grant recipients, 45 percent of respondents cited a decrease in canine coughing and 54 percent of the establishments saw an improvement in the overall health of the dogs as a result of the addition of the CIV vaccine.  More than half responded positively when asked if they intended to add the canine influenza vaccination to standard protocol.

"Vaccinating dogs in shelters and rescues is an important step to help build community immunity against canine influenza because they are adopted out into various locations and move from state to state," said Liz Neuschatz, Executive Director of the Petfinder.com Foundation. "Thanks to the generosity of Merck Animal Health, thousands of rescue and shelter dogs across the country are protected against this highly contagious disease, which supports our efforts to keep them healthy and adoptable to provide greater assurance to adopting families."

Dog flu has been confirmed in 38 states and continues to be a growing problem throughout the U.S.  Dogs at ris
'/>"/>

SOURCE Petfinder.com Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bayer HealthCare Provides Nearly $2.5 Million to Advance Hemophilia Research and Patient Care
2. Nearly 7,000 Participate in Cardinal Healths Largest-Ever Annual Trade Show for Independent Pharmacies
3. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
4. Drug-Related Poisoning The Cause For Nearly 700,000 Emergency Department Visits a Year, According to New Research
5. Six Health Plans Pay $1.5 Million in Incentives to Create Medical Homes for Nearly Half a Million Hudson Valley Residents
6. Ohio Business, Health Care Leaders Collaboration to Improve Patient Safety Results in Estimated Annual Savings of Nearly $13 Million
7. The Hepatitis C Virus Drug Market Will Nearly Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
8. Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015
9. The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
10. In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
11. Southwest Hospitals MRI Centers Commitment to State-of-the-Art Technology at the Heart of Nearly 20-Year Relationship with MedInformatix RIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Solutions LLC today announced the launch of their ... a minimally invasive, Board Certified, OB/GYN surgeon Dr. ... improve patient and surgical team safety.  This proprietary device ... and reload sutures with an efficient, one-handed motion resulting ...
... (Nasdaq: BMRN ) announced today that the ... study (PKU-016) to evaluate the effects of Kuvan (sapropterin ...  BioMarin expects to report results in the first half ... will provide quantitative data regarding the neuropsychiatric effects of ...
Cached Medicine Technology:Equinox Surgical Solutions Launches Flagship Product, SutureAssist® 2BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU 2BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... (Providence, RI)--- EpiVax, Inc, a leader in the field ... funding from the Juvenile Diabetes Research Foundation (JDRF), the ... to develop Epi-13, a novel therapeutic for the prevention ... chronic autoimmune disease that affects up to three million ...
... 2007 - Diseases that cause neurons to break-down, ... (Mad Cow Disease), continue to be elusive to ... from University of Michigan researchers demonstrates an unpredicted ... neuron health., In a study released in PNAS, ...
... ElBaradei will join more than 100 leading public figures, ... in New York on 29 October to mark the ... the US based National Foundation for Cancer Research (NFCR). ... PACT Fund at NFCR, Americans can support the IAEA ...
... is generally considered to be safe with a low ... tube can lead to serious complications. , The ... Dr. Imamura of Aichi Medical University Hospital. It was ... Gastroenterology. , An 86-year-old woman with gastrostomy tube feeding ...
... ALTO, Calif., Oct. 25 ASTRO Booth # ... today announced that it has developed,groundbreaking technology for ... of volumetric arc therapy. Varian,s new RapidArc(TM),radiotherapy technology* ... to deliver more precise forms of intensity-modulated radiation,therapy ...
... Coley,Pharmaceutical Group, Inc. (Nasdaq: COLY ), today announced ... 4:30 p.m. Eastern Time on November,1, 2007 to discuss ... live audio broadcast or the subsequent archived recording,of the ... Coley website,at http://www.coleypharma.com . Please log onto Coley,s ...
Cached Medicine News:Health News:EpiVax receives JDRF program funding to develop diabetes drug using natural 'regulatory' T-cells 2Health News:U-M scientists find new causes for neurodegeneration 2Health News:IAEA and NFCR join forces to fight cancer in developing world 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 3Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 4Health News:Coley Pharmaceutical Group to Report Third Quarter Results on November 1, 2007 2
Curved shafts with fine pointed tips. Smooth handle with dull finish....
Delicate curved shafts with light crisscross serrations. Serrated handle with polished finish. Most popular size or model....
Delicate cross serrated lightly curved tips with serrated handle and polished finish. Most popular size or model....
Delicate lightly curved tips, 1 x 2 mouse style teeth. Serrated handle with polished finish....
Medicine Products: